

## Programme

### 29<sup>th</sup> October

15.45-16.15. Registration and congress documentation

16.15. Opening

Mariano Barbacid (Fundación Areces), Jesús San Miguel, Ignacio Melero, Jose Luis Pérez Gracia, Pedro Berraondo

16.30 – 17.00. Keynote Lecture

*Chair: Pedro Berraondo. CIMA. Ignacio Melero. CIMA y CUN*

Future of cancer immunotherapy: Enhancement or normalization?

*Lieping Chen. Yale. USA*

17.00 – 18.00. Break

18.00 – 20.40. Exploiting tumor antigenicity

*Chair: Juanjo Lasarte. CIMA. Pablo Sarobe. CIMA*

18.00. The Yin and Yang of Cancer Immunotherapy Combinations

*Daniel Chen. Roche Genentech. USA*

18.40. Individualizing Cancer Immunotherapy

*Ugur Sahin. Biontech. Germany*

19.20. Turning an immunologically cold tumor hot: lessons learned from prostate cancer

*James Gulley. NIH. USA*

20.00. Radiotherapy and immunotherapy shoulder to shoulder into the fray

*Silvia Formenti. Cornell. USA*

### 30<sup>th</sup> October

09.00 – 10.00. Title: Immunotherapy development: industrial view and pipelines (1)

*Chair: Jose Luis Pérez Gracia. CUN, Felipe Calvo. Hospital Gregorio Marañón. Madrid*

09.00. Novel Drug Combinations for Cancer Immunotherapy

*Nils Lonberg. BMS. USA*

09.20. Medimmune cancer immunotherapy approach

*Bahija Jallal. Medimmune. USA*

09.40. MSD cancer immunotherapy approach

*David Kaufman. MSD.*

10.00 – 10.40. Round table discussion

10.40 – 11.00. Coffee break

11.00 – 12.20. Immunotherapy development: industrial view and pipelines (2)

*Chair: Luis Paz-Ares. Hospital Universitario Doce de Octubre. Madrid. Spain, Luis Montuenga. CIMA*

11.00. *Immuno-oncology Therapeutic Strategy and Pipeline*

*Philip Gotwals. Novartis. USA*

11.20. *Building a Next-Generation Immuno-Oncology Pipeline in a Competitive Space: Perspectives from a “New Kid on the Block”*

*Lazslo Radvanyi. Merck Serono. USA*

11.40. *A therapeutic strategy to target cold tumors*

*Eric Borges. Boehringer. Austria*

12.00. *The Lilly Immunooncology pipeline: enabling rational combinations*

*Michael Kalos. Lilly. USA*

12.20 – 12.40. Round table discussion

12.45- 14.00- Lunch break

14.00-14.30. Keynote lecture

*Chair: Ignacio Melero. CIMA y CUN, Ruth Vera. Hospital de Navarra*

Clinical development of lung cancer immunotherapy

*Luis Paz-Ares. Hospital Universitario Doce de Octubre. Madrid. Spain*

14.30 – 16.30. Immunotherapy based on evidence

*Chair: Ruben Pio. CIMA, María Rodríguez. CIMA y CUN*

14.30. Targeting immune modulation at the tumour site

*Sergio Quezada. UCL. UK*

15.10. Anti-cancer immune therapy of melanoma

*Mario Sznol. Yale. USA*

15.50. Exploiting radiotherapy in immunotherapy combinations

*Timothy Illidge. The University of Manchester. UK*

16.30 – 18.30. Immunotherapy biomarkers, working in the tissue

*Chair: Dolores Lozano. CUN, Miguel Idoate. CUN*

16.30. Understanding the tumor immune composition using multiplexed quantitative approaches

*Kurt Schalper. Yale. USA*

17.10. Diagnostics in the era of Cancer Immunotherapy

*Priti Hegde. Roche Genentech. USA*

17.50. Role of Immunotherapy in Hodgkin and non-Hodgkin Lymphomas

*Scott J. Rodig. Brigham and Women's Hospital. USA*

### 31<sup>st</sup> October

09.00 – 11.00. TNFR costimulation in action

*Chair: David Escors. Navarrabiomed. Spain, Fernando Pastor. CIMA*

09.00. CD40 stimulation: the rules of a complex game

*Ann White. UCB Celltech. UK*

09.40. Moving forward CD137-based immunotherapies

*Ignacio Melero. CIMA y CUN*

10.20 GITR and 4-1BB in chronic viral infection: implications for cancer therapy

*Tania Watts. University of Toronto. Canada*

11.00 – 11.30. Coffee break

11.30 – 14.10. Genetics and genetic intervention for better immunotherapies

*Chair: Cristian Smerdou. CIMA, Rubén Hernández Alcoceba. CIMA*

11.30. Identification of immunoreactive microsatellite stable (MSS) colorectal cancer for potential immune interventions

*Nicolas J Llosa. Johns Hopkins. USA*

12.10. Deconstructing the T cell Receptor signaling nanomachine

*Balbino Alarcón. CBM. Spain*

12.50. Viruses and IFN $\alpha$ / $\beta$  in immunotherapy

*Pedro Berraondo. CIMA*

13.30. Viral gene therapies

*Ramón Alemany. VCN. Spain*

14.10 – 15.30. Lunch break

15.30 – 17.40. Exploiting new tools to improve immunotherapy

*Chair: Susana Inogés. CUN, Ignacio Gil Bazo. CUN*

15.30. Complement in cancer immunotherapy

*Rubén Pio. CIMA. Spain*

16.10. Patient-derived tumor models for immunotherapy development

*Miguel Sanmamed. Yale. USA*

17.00. Identifying T cells specific against cancer

*Alena Gros. Vall d'Hebron. Spain*

Event supported by:



With the collaboration:



## International Symposium: "Trailblazing in cancer Immunotherapy"

OCTOBER, 29<sup>th</sup> -31<sup>st</sup>



### Fundación Ramón Areces

#### VENUE

Modern art museum. University of Navarra.  
Pamplona, Spain

#### SYMPOSIUM COORDINATORS

Dr. Ignacio Melero  
Dr. Pedro Berraondo  
Dr. Jose Luis Pérez Gracia

#### ORGANIZERS

Fundación para la Investigación Médica Aplicada  
Clínica Universidad de Navarra

#### CONTACT

[simposioareces@unav.es](mailto:simposioareces@unav.es)

#### REGISTRATIONS

<http://simposioareces2017.viajesarga.com>